Demographic and clinical data
| Transplants | Healthy controls | p Value | |||
|---|---|---|---|---|---|
| Total, n | 54 | 31 | |||
| Male, n (%) | 32 | (59.3) | 18 | (58.1) | NS |
| Age, years (SD) | 60 | (9.47) | 41 | (13.4) | <0.0001 |
| Aetiology, n (%) | |||||
| HCV | 18 | (33.3) | |||
| ALD | 7 | (13.0) | |||
| PSC | 7 | (13.0) | |||
| PBC | 6 | (11.1) | |||
| ALF | 5 | (9.3) | |||
| Cryptogenic/NASH | 3 | (5.6) | |||
| Subacute | 2 | (3.7) | |||
| AIH | 1 | (1.9) | |||
| Other | 5 | (9.3) | |||
| Time since LT, days (range) | 2010 | (103–7773) | |||
| Immunosuppression, n (%) | (data missing from 2 patients) | ||||
| Tacrolimus | 43 | (79.6) | |||
| Sirolimus | 2 | (3.7) | |||
| Ciclosporine | 4 | (7.4) | |||
| Corticosteroid | 22 | (40.7) | |||
| Mycophenolate | 14 | (25.9) | |||
| Unknown | 2 | (3.7) | |||
| Post-transplant biopsy available, n (%) | 31 | (57.4) | |||
| Episode of rejection, n (%) | 5 | (9.4) | |||
| Patients with HCV | |||||
| Number treated for HCV, n (%) | 5/18 | (27.8) | |||
| Successful treatment, n (%) | 0/5 | (0) | |||
| Viraemic, n (%) | 18/18 | (100) | |||
| Mean viral load IU/mL (range) | 3.59×106 | (8.25×103–1.08×107) | |||
| Lab Data (range, SD) | |||||
| AST, IU/L | 38.6 | (16–119, 25) | |||
| INR | 1.1 | (0.89–2.71, 0.49) | |||
| Albumin, g/L | 39.9 | (24–46, 4.6) | |||
| Bilirubin, μmol/L | 11.4 | (3–50, 8.6) | |||
| Platelets, ×109/L | 236.9 | (73–530, 105) | |||
| Tacrolimus level, ng/mL | 5.11 | (0.5–14.9, 2.7) | |||
ALD, alcohol-related liver disease; AIH, autoimmune hepatitis; ALF, acute liver failure; AST, aspartate transaminase; INR, international normalised ratio; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.